Jefferies downgraded IGM Biosciences (IGMS) to Hold from Buy with a price target of $2, down from $48, after the company discontinued all ...

Truist analyst Asthika Goonewardene lowered the firm’s price target on IGM Biosciences (IGMS) to $2 from $12 and keeps a Hold rating on the ...

Braman Motors' lawyers believe their client is the first ERISA plan sponsor to join a big group of plaintiffs with cases ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

The rising prevalence of diabetes is anticipated to drive the expansion of the semaglutide market in the coming years.